Search
Washington Paid Clinical Trials
A listing of 1690 clinical trials in Washington actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
733 - 744 of 1690
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Location
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Washington is currently home to 1690 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Bellevue. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Type 2 Diabetes Clinical Trial
Recruiting
Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.
Conditions:
Type 2 Diabetes
Diabetes Mellitus Type 2 in Obese
Diabetes Type Two
Type 2 Diabetes Mellitus
Diabete Type 2
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Fecal Microbiota Transplant and Dietary Fiber Supplementation for the Treatment of Gut Graft Versus Host Disease
Recruiting
This phase I trial studies how well fecal microbiota transplant and dietary fiber supplementation work in treating patients with gut graft versus host disease. Fecal microbiota transplant entails inoculating donor stool into a recipient's gastrointestinal tract. Changing the gut microbiome by fecal microbiota transplant and fiber supplementation may help treat gut graft versus host disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Intestinal Graft Versus Host Disease
Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age With Partial-onset (Focal) Seizures
Recruiting
Primary objective: To evaluate the safety and tolerability of cenobamate in pediatric subjects 2-17 years of age with partial-onset (focal) seizures
Gender:
ALL
Ages:
Between 2 years and 18 years
Trial Updated:
03/20/2025
Locations: MultiCare Institute - Mary Bridge Children's Neurology, Tacoma, Washington
Conditions: Partial Epilepsy
Cephea Early Feasibility Study
Recruiting
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Swedish Medical Center, Seattle, Washington
Conditions: Mitral Regurgitation
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
Recruiting
Early diabetic kidney disease (DKD) occurs in 50-70% of youth with type 2 diabetes (T2D) and confers high lifetime risk of dialysis and premature death. Youth-onset T2D typically manifests during or shortly after puberty in adolescents with obesity. Epidemiological data implicate puberty as an accelerator of kidney disease in youth with obesity and diabetes and the investigators posit that the link between puberty and T2D-onset may explain the high burden of DKD in youth-onset T2D. A better unde... Read More
Gender:
ALL
Ages:
Between 8 years and 14 years
Trial Updated:
03/20/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Type 2 Diabetes Mellitus, Diabetic Kidney Disease, Adolescent Obesity, Pre Diabetes, Kidney Hypoxia, Puberty
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(efocipegtrutide) in Subjects
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/20/2025
Locations: University of Washington (UW) - Harborview Medical Center (HMC) - Hepatitis and Liver Clinic, Seattle, Washington
Conditions: NASH - Nonalcoholic Steatohepatitis
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
Recruiting
This is a Phase 1, open-label, dose-escalation, and dose-expansion, with a gated randomization portion, study to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic and clinical activity of AB680 in combination with Zimberelimab (AB122), nab-paclitaxel and gemcitabine in participants with advanced pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Medical Oncology Associates, Spokane, Washington
Conditions: Advanced Pancreatic Cancer
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Recruiting
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/20/2025
Locations: Swedish Cancer Institute, Seattle, Washington
Conditions: Non-Small Cell Lung Cancer
ColoCare Study - Colorectal Cancer Cohort
Recruiting
ColoCare is an international prospective cohort study of stage I-IV colorectal cancer patients (ICD-10 C18-C20).
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
03/20/2025
Locations: FHCRC, Seattle, Washington
Conditions: Colorectal Cancer
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
Recruiting
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older.
Overall, the study is designed to address the following goals:
* Assess the safety profile of the candidate... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
03/19/2025
Locations: Velocity Clinical Research Seattle- Site Number : 8400019, Seattle, Washington
Conditions: Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA).
The primary objective is to evaluate the effect of seladelpar treatment at Week 52 compared to placebo based on normalization of alkaline phosphatase (ALP) defined by a composite endpoint of ALP ≤ 1.0× upper limit of normal (ULN) and ≥ 15% decrease from baseline in PBC participants with... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/19/2025
Locations: Velocity Clinical Research - Seattle, Seattle, Washington
Conditions: Primary Biliary Cholangitis
A Study to Investigate the Efficacy and Safety of Dupilumab Therapy Compared With Placebo in Participants Aged ≥18 Years With Moderately to Severely Active Ulcerative Colitis With an Eosinophilic Phenotype (LIBERTY-UC SUCCEED (Study in UC for Clinical Efficacy Evaluation of Dupilumab))
Recruiting
The protocol of this Phase 2 clinical trial consists of a double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy and safety of dupilumab in participants with moderately to severely active Ulcerative Colitis (UC) with an eosinophilic phenotype.
Screening period: 2 to up to 4 weeks
Treatment period:
52-week investigational medicinal product (IMP) intervention (dupilumab or matching placebo) from Week 0 to Week 52 Open-label arm (optional): administration of... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Washington Gastroenterology - Bellevue- Site Number : 8400025, Bellevue, Washington
Conditions: Colitis Ulcerative
A Study of GlcNAc on Tear Production in NGLY1-CDDG
Recruiting
In patients with NGLY1-CDDG, the disorder can lead to eye damage due to not being able to produce enough tears. This study is being done to see if the dietary supplement, GlcNAc, improves tear production in patients with NGLY1-CDDG.
Gender:
ALL
Ages:
Between 1 year and 60 years
Trial Updated:
03/19/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: NGLY1 Deficiency